Adverum Biotechnologies (ADVM) Appoints Rupert D’Souza as CFO

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert D’Souza, Ph.D., M.B.A., has joined Adverum as the company’s chief financial officer (CFO). Dr. D’Souza will serve as a member of Adverum’s executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies. Dr. D’Souza will provide leadership for the company’s financial operations and planning, accounting, procurement, and select other functions.

“On behalf of the entire company, I am delighted to welcome Rupert to Adverum and look forward to partnering with him as we advance the company’s strategy together,” said Dr. Laurent Fischer, president and chief executive officer at Adverum Biotechnologies. “As CFO, Dr. D’Souza will play a critical role as we shape and build the company. This includes augmenting our highly experienced executive team to fulfill the promise of our pipeline, including the development of ADVM-022 in wet age-related macular degeneration. I very much look forward to his service and counsel over the coming years.”

“I was drawn to Adverum by the company’s potential transformative gene therapy treatments for ocular and rare diseases,” said Rupert D’Souza, Ph.D., M.B.A., chief financial officer of Adverum Biotechnologies. “With Adverum’s strong financial position and projected cash runway into 2024, I look forward to leveraging my financial expertise to progress the company’s plans to advance a Phase 2 clinical trial in wet AMD next year, and to play an integral role in Adverum achieving its full potential as a diversified gene therapy company.”

Dr. D’Souza most recently served as chief financial officer consultant at Replay Holdings, LLC, a venture capital-funded, gene therapy-focused, biotechnology holding company, where he was responsible for leading all finance and human resources activities. Prior to Replay Holdings, Dr. D’Souza was the founder and chief financial officer consultant at RMND LLC, a business development agency. Before that Dr. D’Souza held roles of increasing responsibility at several companies, including, Armanino LLP, BioMarin Pharmaceuticals, UTStarcom Inc., and Genentech.

Dr. D’Souza received a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Bombay, a Ph.D. in Chemical and Biomolecular Engineering from Georgia Institute of Technology, and an M.B.A. from the University of Chicago Booth School of Business.

You May Also Be Interested In

• Sana Biotechnology (SANA) Announces Resignation of Douglas Williams
• Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
• 22nd Century Group (XXII) Announces Resignation of Sullivan and Mish from Board